undamentalytics Newsletter
Sign in

Cryoport, Inc. (CYRX) stock

Add to watchlist

Add holding +

NASDAQ: CYRX Nasdaq Life Sciences Tools & Services Next results ~November 5, 2026

C Fundamentals grade

Cryoport, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$8.2

Valuation models combined (3)

Base case. Range ~$7.2–$13. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Cryoport, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
  • Funds99 adding, 64 cuttingOf 35 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cryoport files

Where Cryoport stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $186m, up 12.1% on a year earlier, slower than the 14.0% growth a quarter earlier. Free-cash-flow margin rose to -10.8% from -22.0% a year earlier. Operating margin widened to -21.2% from -25.8%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 6 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $8.08 a share, against a share price of $18.60.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Cryoport, Inc.'s trailing-twelve-month revenue grew 12.1% year on year, with a free-cash-flow margin of -10.8%. Where it stands out: long-term debt as % of assets of 0.1% ranks 3 of 35 life sciences tools & services companies we cover.

Current signal Net margin compressing: TTM net margin fell to -20.1%, down 67.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 4.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -21.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -10.8% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 47% and a beta of 1.6 against the S&P 500.
  • Below peers: change in growth rate. Change in growth rate of -1.8pp ranks 41 of 54 life sciences tools & services companies we cover (median +0.4pp).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.20 against an average estimate of -$0.18: missed by 9.1%
Revenue
$49m, up 7.7% on a year earlier
Share reaction
-0.9% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.17

Cryoport's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.1%
  • 1 week-8.8%
  • 1 month-6.9%
  • This year+69.1%
  • 1 year+75.6%
  • 5 years-80.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$186M
Operating margin
-21.2%
Net margin
-20.1%
EPS (TTM, diluted)
$-0.75

Growth

Revenue growth
+12.1%
Change in growth rate
−1.8 pts
Share count change
+0.6%

Cash

Free cash flow (TTM)
-$20.2M
FCF margin
-10.8%
Stock pay % of revenue
5.2%

Earnings

Last results
August 6, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cryoport, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Cryoport, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.32 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.2 ~$5.8–$8.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$13 ~$10–$30 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.1 ~$7.1–$9.3 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$8.2 ~$7.2–$13 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cryoport, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$3.24$8.59$11.03$16.46$43.88$59.17$17.35$15.49$7.78$9.60$16.23
Market value$46m$197m$311m$550m$1.7bn$2.7bn$850m$755m$384m$481m$813m
+ Net debt (− = net cash)−$5m−$15m−$23m−$47m$78m$265m$378m$344m$164m−$64m−$82m
Enterprise value$42m$182m$289m$502m$1.8bn$3.0bn$1.2bn$1.1bn$548m$417m$731m
Multiples
Price / sales 6.0x16.5x15.9x16.2x21.5x12.2x3.6x4.5x2.4x2.7x4.4x
Price / earnings —————————6.1x—
Price / free cash flow ———————————
EV / EBITDA —————n/m—————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

19 /100

Weak moat

How hard Cryoport's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -4.5% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 45.6%, moving by 3.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -29.8%; its worst year was -133.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -20.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 19.3% over five years; stock-based pay has been a median 11.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $49m and EPS of −$0.17 (range −$0.18 to −$0.17) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.77 −14% $195m +11%
Next −$0.66 +14% $215m +10%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.0% on 90 days ago. In the last 30 days, 1 analyst raised Cryoport, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Cryoport, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.73 Current fiscal year, 60 days ago: −$0.77 Current fiscal year, 30 days ago: −$0.77 Current fiscal year, 7 days ago: −$0.77 Current fiscal year, Now: −$0.77 −$0.77 Next fiscal year, 90 days ago: −$0.62 Next fiscal year, 60 days ago: −$0.66 Next fiscal year, 30 days ago: −$0.66 Next fiscal year, 7 days ago: −$0.66 Next fiscal year, Now: −$0.66 −$0.66

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.73−$0.62
60 days ago −$0.77−$0.66
30 days ago −$0.77−$0.66
7 days ago −$0.77−$0.66
Now −$0.77−$0.66

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.20 −9.1%
Mar 2026 −$0.19 −$0.19 +1.8%
Dec 2025 −$0.21 −$0.17 +17.6%
Sept 2025 −$0.19 −$0.13 +31.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Cryoport, Inc.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

9 analysts, Oct 2026
Buy889%
Hold111%
Sell00%

Monthly trend

  1. Oct 20261719
  2. Sep 20261719
  3. Aug 20261719
  4. Jul 20261719

Counts of recommendations published by analysts covering Cryoport, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.0%
of tradable shares
Days to cover
3.29
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
95%
of shares
Held by insiders
3.9%
of shares
Employees
684
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +75.6%

$9.24 on October 31, 2025 to $16.23

ThenNowEffect
Revenue (last 12 months) $166m $186m +12.1%
P/S multiple 2.8x 4.4x +57.6%
Share count 50m 50m −0.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +60.7%

$10.10 on November 3, 2023 to $16.23

ThenNowEffect
Revenue (last 12 months) $241m $186m −22.5%
P/S multiple 2.0x 4.4x +113.7%
Share count 49m 50m −2.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CYRX+35%−71%−11%−50%+23%+69%
Industry peers (median)+4%−51%−3%−13%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CYRX50%42%33%50%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CYRX−41%−73%−65%−71%−47%−32%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from November 4, 2021 to March 10, 2025. Getting back needed a 1672% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.72 – $18.64
From 52-week high
−12.9%
vs 50-day average
−4.2%
vs 200-day average
+21.8%
Volatility (1 year)
47%
Beta vs S&P 500
1.63

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±13.5%
After a week
7 up, 5 down
typical move ±15.6%
After a month
11 up, 1 down
typical move ±23.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −0.9% +0.5% −0.8% +3.7%
May 4, 2026 +17.8% +0.4% +27.2% +59.4%
March 3, 2026 +6.5% −0.2% −4.0% +3.7%
November 4, 2025 −5.6% −0.8% −2.1% +9.3%
August 6, 2025 +21.7% +0.7% +34.7% +53.6%
May 7, 2025 +26.0% +1.1% +16.8% +26.4%
March 4, 2025 +37.7% −0.1% +38.5% +28.3%
November 7, 2024 −3.6% +1.2% −8.0% +3.9%
August 6, 2024 +3.9% +0.2% +9.6% +9.8%
May 7, 2024 −17.5% +0.1% −16.0% −30.6%
March 12, 2024 −12.3% +0.9% +1.0% +10.3%
November 8, 2023 +8.9% −0.7% +28.1% +46.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cryoport, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cryoport, Inc.
$100M $150M $200M $250M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $236.4M Revenue (TTM), FY23 Q4: $168.7M Revenue (TTM), FY24 Q1: $143.1M Revenue (TTM), FY24 Q2: $125.8M Revenue (TTM), FY24 Q3: $108M Revenue (TTM), FY24 Q4: $156.8M Revenue (TTM), FY25 Q1: $160.5M Revenue (TTM), FY25 Q2: $166.3M Revenue (TTM), FY25 Q3: $172.2M Revenue (TTM), FY25 Q4: $176.2M Revenue (TTM), FY26 Q1: $182.9M Revenue (TTM), FY26 Q2: $186.5M $186.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $236.4M
FY23 Q4 $168.7M
FY24 Q1 $143.1M
FY24 Q2 $125.8M
FY24 Q3 $108M
FY24 Q4 $156.8M
FY25 Q1 $160.5M
FY25 Q2 $166.3M
FY25 Q3 $172.2M
FY25 Q4 $176.2M
FY26 Q1 $182.9M
FY26 Q2 $186.5M
Revenue growth, TTM YoY Cryoport, Inc.
-100% -50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 1.3% Revenue growth, TTM YoY, FY23 Q4: -28.9% Revenue growth, TTM YoY, FY24 Q1: -42.2% Revenue growth, TTM YoY, FY24 Q2: -47.7% Revenue growth, TTM YoY, FY24 Q3: -54.3% Revenue growth, TTM YoY, FY24 Q4: -7.1% Revenue growth, TTM YoY, FY25 Q1: 12.1% Revenue growth, TTM YoY, FY25 Q2: 32.1% Revenue growth, TTM YoY, FY25 Q3: 59.4% Revenue growth, TTM YoY, FY25 Q4: 12.4% Revenue growth, TTM YoY, FY26 Q1: 14.0% Revenue growth, TTM YoY, FY26 Q2: 12.1% 12.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 1.3%
FY23 Q4 -28.9%
FY24 Q1 -42.2%
FY24 Q2 -47.7%
FY24 Q3 -54.3%
FY24 Q4 -7.1%
FY25 Q1 12.1%
FY25 Q2 32.1%
FY25 Q3 59.4%
FY25 Q4 12.4%
FY26 Q1 14.0%
FY26 Q2 12.1%
Operating margin (TTM) Cryoport, Inc.
-200% -150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -23.8% Operating margin (TTM), FY23 Q4: -59.6% Operating margin (TTM), FY24 Q1: -75.5% Operating margin (TTM), FY24 Q2: -133.3% Operating margin (TTM), FY24 Q3: -152.0% Operating margin (TTM), FY24 Q4: -77.6% Operating margin (TTM), FY25 Q1: -69.4% Operating margin (TTM), FY25 Q2: -25.8% Operating margin (TTM), FY25 Q3: -23.0% Operating margin (TTM), FY25 Q4: -20.9% Operating margin (TTM), FY26 Q1: -21.4% Operating margin (TTM), FY26 Q2: -21.2% -21.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -23.8%
FY23 Q4 -59.6%
FY24 Q1 -75.5%
FY24 Q2 -133.3%
FY24 Q3 -152.0%
FY24 Q4 -77.6%
FY25 Q1 -69.4%
FY25 Q2 -25.8%
FY25 Q3 -23.0%
FY25 Q4 -20.9%
FY26 Q1 -21.4%
FY26 Q2 -21.2%
FCF margin (TTM) Cryoport, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -16.9% FCF margin (TTM), FY23 Q4: -26.6% FCF margin (TTM), FY24 Q1: -31.6% FCF margin (TTM), FY24 Q2: -34.9% FCF margin (TTM), FY24 Q3: -32.5% FCF margin (TTM), FY24 Q4: -23.3% FCF margin (TTM), FY25 Q1: -22.9% FCF margin (TTM), FY25 Q2: -22.0% FCF margin (TTM), FY25 Q3: -19.7% FCF margin (TTM), FY25 Q4: -15.2% FCF margin (TTM), FY26 Q1: -13.8% FCF margin (TTM), FY26 Q2: -10.8% -10.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -16.9%
FY23 Q4 -26.6%
FY24 Q1 -31.6%
FY24 Q2 -34.9%
FY24 Q3 -32.5%
FY24 Q4 -23.3%
FY25 Q1 -22.9%
FY25 Q2 -22.0%
FY25 Q3 -19.7%
FY25 Q4 -15.2%
FY26 Q1 -13.8%
FY26 Q2 -10.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-KT, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Mar 2011 2012 Mar 2012 2013 Mar 2013 2014 Mar 2014 2015 Mar 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 1 3 4 8 12 20 34 79 223 237 169 157 176 186
Gross profit −1 −1 −0 0 1 3 6 10 17 36 97 104 75 70 83 88
EBITDA −5 −7 −6 −5 −5 −8 −7 −8 −15 −20 2 −9 −73 −91 −9 −14
Operating income −6 −7 −6 −5 −6 −9 −8 −9 −18 −30 −18 −32 −101 −122 −37 −40
Net income −6 −8 −6 −20 −7 −13 −8 −10 −18 −33 −276 −37 −100 −115 78 −37
Diluted EPS −$1.84 −$1.08 −$0.68 −$1.60 −$0.81 −$0.93 −$0.34 −$0.34 −$0.55 −$1.94 −$6.18 −$0.93 −$2.21 −$2.49 $1.40 −$0.75
Growth (year on year)
Revenue — +16.9% +98.1% +141.7% +47.9% +95.1% +55.7% +64.2% +72.9% +131.9% +182.9% +6.6% −28.9% −7.1% +12.4% +12.1%
Net income — — — — — — — — — — — — — — — −147.3%
Diluted EPS — — — — — — — — — — — — — — — −147.0%
Margins
Gross margin −174.0% −150.6% −44.3% 16.4% 29.7% 40.4% 49.9% 52.2% 51.1% 46.2% 43.4% 43.8% 44.7% 44.4% 47.1% 47.1%
EBITDA margin <−999% <−999% −538.9% −179.2% −137.1% −109.3% −60.5% −39.7% −45.0% −25.6% 1.1% −3.9% −43.3% −58.0% −5.2% −7.4%
Operating margin <−999% <−999% −574.7% −190.9% −142.1% −114.2% −66.0% −44.0% −52.1% −38.1% −8.0% −13.4% −59.6% −77.6% −20.9% −21.2%
Net margin <−999% <−999% −579.9% −735.6% −178.6% −170.8% −66.1% −48.7% −54.0% −41.5% −123.8% −15.7% −59.0% −73.2% 44.4% −20.1%
Free-cash-flow margin <−999% <−999% −449.0% −169.9% −106.7% −88.3% −44.3% −31.9% −19.6% −30.2% −7.1% −10.1% −23.4% −21.4% −14.2% −10.7%
Cash flow
Cash from operations −5 −7 −5 −4 −4 −6 −4 −3 −1 −15 8 −2 −1 −16 −9 8
Capital spending 0 0 0 0 0 1 2 3 5 9 24 22 39 17 16 28
Free cash flow −5 −7 −5 −5 −4 −7 −5 −6 −7 −24 −16 −24 −40 −34 −25 −20
Stock-based pay 1 0 1 1 1 3 4 5 17 9 15 20 20 17 10 10
Free cash flow after stock pay −6 −7 −6 −5 −5 −10 −9 −12 −23 −33 −31 −44 −59 −50 −35 −30
Balance sheet
Cash — — — — — 5 15 37 47 37 139 29 35 34 250 269
Total debt 2 0 1 — 1 0 0 15 0 115 404 407 379 198 186 187
Net debt (negative = net cash) — — — — — −5 −15 −23 −47 78 265 378 344 164 −64 −82
Diluted shares 3m 9m 10m 12m 15m 14m 23m 28m 33m 39m 46m 49m 49m 49m 50m 50m
Returned to shareholders
Buybacks — — — — — — — — — 0 0 38 — — 10 —
Total returned — — — — — — — — — 0 0 38 — — 10 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $756m
Short-term assets $460mLonger-term assets $296m
What it owes, and who funded it · $756m
Short-term liabilities $221mLonger-term liabilities $44mShareholders' equity $491m
  • Short-term assets cover short-term liabilities $460m of assets due within a year against $221m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $460m short-term assets against $44m of longer-dated liabilities.
  • More cash than debt $269m of cash against $985,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt $8m of operating cash flow against $985,000 of debt.
  • Operating profit covers interest at least five times over Operating income of −$40m against $2m of interest.

From Cryoport, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$48M
Diluted share count
+0.6%
year over year
R&D spending
9.5%
of revenue
Sales & admin spending
58.8%
of revenue
Days sales outstanding
71 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated CYRX CTKB MRVI GRAL PACB QTRX Median
Revenue, last 12 months $186m $207m $209m $165m $159m $153m $229m
Revenue growth, last 12 months 12.1% 5.4% −5.0% 23.1% 2.0% 22.0% 6.9%
Revenue growth, 3-year average −8.2% 5.6% −27.3% — 2.9% 11.1% 2.9%
Revenue growth, latest quarter 7.7% 5.6% 8.5% 25.7% −1.9% 34.4% 8.5%
Gross margin 47.1% 53.2% 34.9% — 36.4% 42.7% 51.9%
Operating margin −21.2% −21.6% −56.1% −338.4% −83.5% −99.6% −14.3%
Operating margin, 3-year average −60.1% −16.1% −73.7% <−999% −250.8% −70.6% −22.4%
Net margin −20.1% −39.0% −37.1% −236.9% −82.5% −80.2% −16.1%
Cash from operations / revenue 4.3% −2.9% −12.1% −178.4% −74.1% −52.7% 1.3%
Free-cash-flow margin −10.8% −5.9% −17.2% −179.2% −77.5% −53.2% −2.2%
Free-cash-flow margin, 3-year average −22.6% 1.7% −14.3% — −104.4% −36.8% 0.6%
Stock pay / revenue 5.2% 10.3% 14.3% 38.9% 21.5% 12.1% 4.4%
Change in share count 0.6% −0.3% 2.3% 18.5% 0.9% 21.0% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 12.1% 6.9% 19 of 54
Change in growth rate Growth -1.8pp +0.4pp 41 of 54
Gross margin Profitability 47.1% 52.0% 28 of 45
Operating margin Profitability -21.2% -14.3% 29 of 52
Net margin Profitability -20.1% -12.2% 29 of 54
Free-cash-flow margin Cash generation -10.8% -1.3% 34 of 54
Stock pay as % of revenue Cash generation 5.2% 4.4% 28 of 53
Long-term debt as % of assets Balance sheet 0.1% 26.3% 3 of 35
Change in share count Balance sheet 0.6% 1.0% 20 of 46
Days sales outstanding Balance sheet 71 days 62 days 36 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Reportable Segment Aggregation Before Other Operating $176M 100.0% ▲ 12.4%
Life Sciences Services $101M 57.3% ▲ 18.4%
Life Sciences Products $75.1M 42.7% ▲ 5.2%
Products and services
Line of business Revenue Share YoY
Services $96.5M 54.8% ▲ 17.6%
Biologistics Solutions $78.1M 81.0% ▲ 16.6%
Biostorage Bioservices $18.4M 19.0% ▲ 22.2%
Products $79.7M 45.2% ▲ 6.6%
Geography
Region Revenue Share YoY
Americas $131M 74.5% ▲ 15.6%
EMEA $25.1M 14.3% ▼ 7.0%
Asia Pacific $19.8M 11.2% ▲ 22.1%

From Cryoport, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$746M
Institutions reporting
183
Shares held vs prior quarter
▲ 3.8%
Positions opened / closed
35 / 15

Top buyers and sellers, Q2 2026: 99 institutions bought and 64 sold ; the biggest buyer was First Eagle Investment Management, LLC (+1.8M shares) and the biggest seller Morgan Stanley (−2.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $66.2M 4.2M 8.9% ▲ 6.0%
Cadian Capital Management, LP $45.9M 2.9M 6.2% ▼ 38.9%
First Eagle Investment Management, LLC $39.9M 2.5M 5.4% ▲ 241.4%
Assenagon Asset Management S.A. $36.2M 2.3M 4.9% ▲ 54.1%
Morgan Stanley $35.7M 2.3M 4.8% ▼ 50.3%
Vanguard Capital Management LLC $33.8M 2.2M 4.5% ▲ 1.6%
Millennium Management LLC $27.1M 1.7M 3.6% ▼ 41.9%
Fred Alger Management, LLC $24.3M 1.5M 3.3% ▼ 9.1%
Geode Capital Management, LLC $20.6M 1.3M 2.8% ▲ 5.1%
Mak Capital One LLC $20.1M 1.3M 2.7% ▼ 10.3%
State Street Corp $16.4M 1.0M 2.2% ▲ 6.4%
Dimensional Fund Advisors LP $15.7M 1.0M 2.1% ▲ 8.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cryoport, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4.6M 14 trades by 5 insiders · 9% under pre-set plans
Net ▼ $4.6M net selling
Insider Date Trade Shares Price Value
Shelton Jerrell President, CEO August 11, 2026 Sell pre-set plan 28,800 $14.91 $429,408
Zecchini Edward J Chief Digital and Tech Officer June 11, 2026 Sell 33,600 $14.47 $486,192
Zecchini Edward J Chief Digital and Tech Officer June 10, 2026 Sell 1,400 $15.23 $21,322
Mandalam Ramkumar Director June 8, 2026 Sell 23,214 $15.44 $358,424
Stefanovich Robert Chief Financial Officer June 4, 2026 Sell 169,427 $16.27 $2.8M
Sawicki Mark W Chief Scientific Officer March 23, 2026 Sell 1,341 $8.18 $10,969
Shelton Jerrell President, CEO March 23, 2026 Sell 2,894 $8.18 $23,673
Stefanovich Robert Chief Financial Officer March 23, 2026 Sell 1,094 $8.18 $8,949
Stefanovich Robert Chief Financial Officer March 16, 2026 Sell 2,743 $8.00 $21,944
Sawicki Mark W Chief Scientific Officer March 16, 2026 Sell 3,235 $8.00 $25,880
Shelton Jerrell President, CEO March 16, 2026 Sell 7,918 $8.00 $63,344
Zecchini Edward J See Remarks March 16, 2026 Sell 2,014 $8.00 $16,112

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 20 trades and filings

No trades in Cryoport, Inc. disclosed in the last 12 months; 20 earlier trades on record.

  • Josh Gottheimer(D-NJ 5):Sale (full), $1,001 - $15,000, traded September 15, 2023, filed October 15, 2023
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded February 28, 2022, filed March 3, 2022
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded January 31, 2022, filed February 1, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 4, 2026
  • March 3, 2026
  • November 4, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Cryoport, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cryoport, Inc. in brief

What does Cryoport, Inc. do?
Cryoport, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Cryoport, Inc.'s stock ticker?
Cryoport, Inc. trades under the ticker CYRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cryoport, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cryoport, Inc. reported revenue of $186M, 12.1% higher than a year earlier, according to its SEC filings.
What is Cryoport, Inc.'s free cash flow?
Cryoport, Inc.'s free-cash-flow margin is -10.8% of revenue over the trailing twelve months, ranking 34 of the 54 life sciences tools & services companies we cover.
Who are Cryoport, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Cadian Capital Management, LP and First Eagle Investment Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cryoport, Inc.'s market cap?
On November 2, 2026, Cryoport, Inc.'s market capitalisation was about $813M and net debt of -$82.4M. Market figures come from third-party market data and may be delayed.
How much debt does Cryoport, Inc. have?
Cryoport, Inc.'s debt-to-equity ratio is 0.2%, from its latest balance sheet (0.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Cryoport, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Cryoport, Inc. are Cytek Biosciences, Inc., Maravai Lifesciences Holdings, Inc., Grail, Inc., Pacific Biosciences Of California, Inc. and Quanterix Corp. The side-by-side comparison below sets their revenue, margins and growth against Cryoport, Inc.'s.
Are insiders buying or selling Cryoport, Inc. stock?
Over the last 12 months, Cryoport, Inc.'s directors and officers reported 0 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Cryoport, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cryoport, Inc. announces its own schedule.